SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
380Hi Tuck, >No terms disclosed, so one wonders how "major" this realpgo-neil-9/4/2007
379XL647 shows benefit in 60% of a 30 patient ph2 trial. Wonder why GSK dropped thpgo-neil-9/4/2007
378>>Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Coltuck-9/4/2007
377Aug 23 (Reuters) - Exelixis Inc (EXEL.O: Quote, Profile, Research) said it agreerkrw-8/23/2007
376gs: Exelixis, Inc. (EXEL): Pipeline on track. Seeking ex-US partner for XL647. mopgcw-8/12/2007
375Dr. West of OncTalk on XL999. This suggests to me this trial may not enroll tootuck-7/31/2007
374Just gsk passing on 647 and updating clinical plans. To pivotal trials nsclc in rkrw-7/26/2007
373gsk could pass on opting in to 647 but I don't think it makes sense for themrkrw-7/26/2007
372I wasn’t joking, but neither am I well-versed on EXEL-GSK dealings. In my experiDewDiligence_on_SI-7/25/2007
371gsk also has an option on 880. Not sure the review has been triggered but it wourkrw-7/25/2007
370Why walk before you have a chance to inspect the groceries? First gsk option irkrw-7/25/2007
369Pull out? You're joking. Skip on the first cpd? Given the milestones, qukeokalani'nui-7/25/2007
368Is GSK pulling out? This PR sounds that way. biz.yahoo.comDewDiligence_on_SI-7/25/2007
367GSK decision coming up.kenhott-7/13/2007
366Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor ReceptoIcebrg-6/27/2007
365Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO scaram(o)uche-6/3/2007
364Abstract No: 18112 Citation: Journal of Clinical Oncology, 2007 ASCO Annual Mekenhott-6/3/2007
363Exelixis Reports Comprehensive XL880 Phase I Data At ASCO Saturday June 2, 8:30 Neil H-6/2/2007
362Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference May 30,LJM-5/30/2007
361Exelixis Initiates Phase II Trial of XL647 in NSCLC Patients Who Have Previouslyscaram(o)uche-5/30/2007
360Exelixis Files IND Application for XL019, a Novel Anticancer Compound Targeting scaram(o)uche-5/24/2007
359mstar: Exelixis EXEL finished its first quarter with a net loss of $24 million,mopgcw-5/6/2007
358x647. Have seen a number of responders with and without activating mutations. keokalani'nui-5/4/2007
357Just to repeat: <i>We recently notified GlaxoSmithKline of our determinatkeokalani'nui-5/3/2007
356Exelixis Announces First Quarter 2007 Financial Results and Business Update Thurmopgcw-5/3/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News